Revolution Medicines (NASDAQ:RVMD) Insider Sells $206,222.04 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Lin Wei sold 2,073 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $206,222.04. Following the sale, the insider directly owned 101,366 shares of the company’s stock, valued at $10,083,889.68. The trade was a 2.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Revolution Medicines Stock Performance

Shares of NASDAQ:RVMD traded up $1.18 during trading on Thursday, reaching $99.29. The stock had a trading volume of 1,485,201 shares, compared to its average volume of 2,335,170. Revolution Medicines, Inc. has a 52 week low of $29.17 and a 52 week high of $124.49. The firm has a market capitalization of $19.68 billion, a price-to-earnings ratio of -16.80 and a beta of 0.99. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16. The stock has a fifty day simple moving average of $103.58 and a two-hundred day simple moving average of $76.24.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same period last year, the company earned ($1.12) EPS. As a group, analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Neutral Sentiment: Jefferies Financial Group initiated coverage of Revolution Medicines, bringing fresh analyst attention that can boost visibility and trading interest but whose impact depends on the firm’s published rating and price target (not specified in the entry). Jefferies Initiates Coverage
• Negative Sentiment: Insider sale — Xiaolin Wang sold 2,010 shares at an average $99.48 (≈$200k); holding fell ~1.70%, leaving ~116k shares. Multiple officer sales on the same day can be read negatively by the market. SEC Filing
• Negative Sentiment: Insider sale — CFO Jack Anders sold 2,753 shares at $99.48 (≈$274k); his stake declined ~2.15%, now ~125.5k shares. SEC Filing
• Negative Sentiment: Insider sale — COO Margaret A. Horn sold 4,583 shares at $99.48 (≈$456k); her ownership fell ~2.83%, leaving ~157.6k shares. SEC Filing
• Negative Sentiment: Insider sale — Mark A. Goldsmith sold 12,871 shares at $99.48 (≈$1.28M); his holding decreased ~4.44%, leaving ~276.7k shares. Larger absolute size may attract investor attention. SEC Filing
• Negative Sentiment: Insider sale — Stephen Michael Kelsey sold 4,302 shares at $99.48 (≈$428k); his stake fell ~1.44%, leaving ~295.4k shares. SEC Filing
• Negative Sentiment: Insider sale — Lin Wei sold 2,073 shares at $99.48 (≈$206k); her holding declined ~2.00%, leaving ~101.4k shares. SEC Filing

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a report on Thursday, January 22nd. UBS Group started coverage on Revolution Medicines in a research report on Friday, February 27th. They set a “buy” rating for the company. Evercore upgraded Revolution Medicines to a “strong-buy” rating in a research note on Wednesday, February 25th. Benchmark reaffirmed an “overweight” rating on shares of Revolution Medicines in a report on Tuesday, February 17th. Finally, Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a research report on Friday, January 9th. Four analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $78.94.

Hedge Funds Weigh In On Revolution Medicines

Several institutional investors and hedge funds have recently added to or reduced their stakes in RVMD. Global Retirement Partners LLC raised its holdings in Revolution Medicines by 1,002.8% in the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after acquiring an additional 361 shares in the last quarter. Indiana Trust & Investment Management Co acquired a new stake in shares of Revolution Medicines during the 4th quarter worth approximately $32,000. Torren Management LLC acquired a new stake in shares of Revolution Medicines during the 4th quarter worth approximately $33,000. Arax Advisory Partners bought a new stake in shares of Revolution Medicines during the fourth quarter valued at approximately $38,000. Finally, Darwin Wealth Management LLC bought a new stake in shares of Revolution Medicines during the fourth quarter valued at approximately $40,000. 94.34% of the stock is currently owned by institutional investors.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.